Pi-Cardia is a global leader in the development of a unique portfolio of non-implant, catheter-based, leaflet modification solutions for treating heart valves.

 

The ShortCut™ device is a safe, simple and effective way to split valve leaflets of a pre-existing valve prior to TAVR in patients at risk for coronary obstruction and is designed to preserve coronary access.

 

ShortCut™ Mitral is designed to split the anterior mitral leaflet prior to TMVR in patients at risk for LVOT obstruction.

 

The Leaflex™ device mechanically scores valve calcification at multiple locations, with the intention of restoring leaflet flexibility and improving valve hemodynamics. It is designed to be a cost-effective, durable standalone treatment for patients with calcified aortic stenosis.

 

The Leaflex™ and ShortCut™ Mitral are investigational devices, limited by United States law for investigational use.​